Cargando…
EB1089 promotes the expression of vitamin D receptor in the intestinal epithelial cell line HT-29 and reduces lipopolysaccharide-induced inflammatory response
BACKGROUND: EB1089 is a vitamin D receptor (VDR) agonist that reduces the inflammatory response. The specific pathway through which the inflammatory response is reduced is unclear, and this study is intended to investigate its effect on the inflammatory response through an LPS (lipopolysaccharide)-i...
Autores principales: | Lu, Dong, Yu, Minghui, Chen, Lu, Ye, Jianqiang, Huang, Liquan, Zhu, Guangwei, Lan, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096417/ https://www.ncbi.nlm.nih.gov/pubmed/35571391 http://dx.doi.org/10.21037/atm-22-1066 |
Ejemplares similares
-
The vitamin D receptor agonist EB1089 can exert its antiviral activity independently of the vitamin D receptor
por: Jaratsittisin, Janejira, et al.
Publicado: (2023) -
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
por: Evans, T R J, et al.
Publicado: (2002) -
A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.
por: Gulliford, T., et al.
Publicado: (1998) -
SAT-353 The Synthetic Vitamin D Analog EB1089 Restricts Adrenocortical Tumor Proliferation in NCI-H295 Xenograft Model
por: Bueno, Ana, et al.
Publicado: (2019) -
Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells
por: Larsen, S S, et al.
Publicado: (2001)